[368] TTF-1 and Napsin-A Double Staining in Lung Adenocarcinoma: Diagnostic Utility in Fine Needle Aspirations.
Nazneen Fatima, Cynthia Cohen, Momin T Siddiqui. Emory University Hospital, Atlanta, GA
Background: Lung cancer is the most common type of cancer in terms of mortality worldwide. Recent FDA approval of Avastin in the treatment of non-squamous cell lung cancer and its contraindication in squamous cell carcinoma (SQCC) has made it crucial to accurately diagnose the different types of non-small cell lung cancers. Immunohistochemistry (IHC) for thyroid transcription factor-1 (TTF-1) is widely used in the diagnosis of lung adenocarcinomas (ADC). It is positive in approximately 75% of lung ADC and negative in most SQCC and ADC of other organs. A new promising marker, Napsin-A, has been detected in the cytoplasm of type 2 pneumocytes and alveolar macrophages. It is an aspartic proteinase involved in the processing of surfactant protein B and is strongly positive in up to 80% of primary lung ADC by IHC. Small cell carcinomas and SQCC of the lung have been shown to be negative for Napsin-A. A combination (Double stain) of these two stains (TTF-1 and Napsin-A) has been proposed to achieve higher sensitivity and specificity.
Design: FNA cell blocks of 36 lung ADC and 26 lung SQCC were studied. IHC was performed on formalin-fixed paraffin-embedded cell blocks. Expression of Napsin-A as cytoplasmic red stain and TTF-1 as nuclear brown stain were identified easily. For positive control, lung ADC was used.
Results:
| TTF-1/Napsin-A Double stain | TTF-1 Alone | Napsin-A Alone | |
| ADC | 27/36 (75%) | 4/36 (11%) | 4/36 (11%) |
| SQCC | 3/26 (11%) | 6/26 (23%) | 0/26 (0%) |
| Sensitivity | Specificity | PPV | NPV | Accuracy | |
| TTF-1/Napsin-A Double Stain | 75% | 88% | 90% | 71% | 80% |